// App-Quantinova.ai

4635 : Comparative cancer cell line profiling differentiates the mechanism of action of different PI3K/mTOR, Aurora kinase and EZH2 inhibitors

Researchers

Presenter

  • Joost C.M. Uitdehaag

Principal Investigators

  • Jeroen A.D.M. de Roos

  • Martine B.W. Prinsen

  • Judith R.F. de Vetter

  • Jelle Dylus

  • Antoon M. van Doornmalen

  • Suzanne J.C. van Gerwen

  • Jos de Man

  • Rogier C. Buijsman

  • Guido J.R. Zaman

Medical Centers

  • Netherlands Translational Research Center B.V, Oss, Netherlands

Locations

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Enhancer of zeste homolog 2

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • EZH2

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved